Risk adjusted net present value: What is the current valuation of Novartis’s Rapcabtagene autoleucel?

Rapcabtagene autoleucel is a gene-modified cell therapy commercialized by Novartis, with a leading Phase II program in Diffuse Large B-Cell Lymphoma.

Dec 13, 2024 - 06:00

Rapcabtagene autoleucel is a gene-modified cell therapy commercialized by Novartis, with a leading Phase II program in Diffuse Large B-Cell Lymphoma.

Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Adicet Bio’s A...

Flu vaccine strategy on the line as new US leaders anticipated to take charge

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Tanzania reports a Marburg outbreak, Africa’s second this year

Tanzania reports a Marburg outbreak, Africa’s second th...

Mar 22, 2023

STAT+: Damages from tornado at Pfizer plant could compound challenges of drug shortages

STAT+: Damages from tornado at Pfizer plant could compo...

Jul 20, 2023

STAT+: Novartis to buy German biotech MorphoSys for $2.9 billion

STAT+: Novartis to buy German biotech MorphoSys for $2....

Feb 5, 2024